Skip to main content

Table 1 Characteristics of the cohort of patients

From: Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients

Characteristics

Items

N (%)

Sex

Female

26 (18.4%)

 

Male

112 (79.4%)

Age

Mean

64

 

Median (range)

66 (30–87)

 

St.dev

11

Portal Vein Thrombosis

No

64 (46.4%)

 

Yes

74 (53.6%)

Tumor location

Right lobe

57 (41.3%)

 

Left lobe

10 (7.2%)

 

Bilateral lobe

71 (51.4%)

Stage T

T1

8 (5.8%)

 

T2

10 (7.2%)

 

T3

120 (86.9%)

Stage N

N0

114 (82.60%)

 

N1

24 (17.4%)

Stage M

M0

116 (84.1%)

 

M1

22 (15.9%)

AJCC Stage

I

7 (5.1%)

 

II

9 (6.5%)

 

III

83 (60.1%)

 

IV

39 (28.3%)

Okuda Stage

I

31 (22.4%)

 

II

107 (77.6%)

BCLC Stage

A

9 (6.5%)

 

B

29 (21.0%)

 

C

100 (72.5%)

Child-Pugh Stage

A

96 (69.6%)

 

B

42 (30.4%)

Hepatitis

No

19 (13.8%)

 

B

71 (51.4%)

 

C

43 (31.2%)

 

B and C

5 (3.6%)

Initial Alpha-fetoprotein (?g/L)

Median (range)

11481 (2.4 – >58300)

Initial white blood count (kU/?L)

Median (range)

5.9 (2.7 – 15.6)

Initial haemoglobin level (g/dL)

Median (range)

12.8 (7.0 – 19.0)

Initial GPT level (U/L)

Median (range)

50.0 (8.8 – 396.0)

Initial total bilirubin level (mg/dL)

Median (range)

0.9 (0.3 – 8.5)

Initial tumor volume (cm3)

Median (range)

516 (28 – 3621)

Total liver volume (cm3)

Median (range)

1587 (548 – 5489)

Dose prescription

45Gy

16 (11.6%)

 

60Gy

114 (82.6%)

 

66Gy

8 (5.8%)

  1. Values refer to number of patients, % to the total number of 138 patients.
  2. AJCC: American joint Committee on Cancer, BCLC: Barcelona Clinic Liver Cancer. HCC: hepatocellular carcinoma. TACE: transarterial chemo-embolisation. RFA: radio-frequency ablation. GPT: Glutamic Pyruvic Transaminase.